Skip to content
2000
Volume 25, Issue 9
  • ISSN: 1389-2002
  • E-ISSN: 1875-5453

Abstract

Background

Dasatinib has been widely used in the treatment of a variety of cancers, such as lung cancer and acute myeloid leukemia. Shenmai injection is a traditional Chinese medicine injection that is often used in antitumor adjuvant therapy. In recent years, dasatinib combined with Shenmai injection has been increasingly used to treat tumors clinically. However, the potential risks and benefits of co-administering Shenmai injection and dasatinib are unclear.

Objective

The study aimed to investigate the potential influence of Shenmai injection on dasatinib pharmacokinetics.

Methods

Twelve rats were selected and randomly divided into two groups: dasatinib alone and a combination of dasatinib and Shenmai injection. To measure the concentration of dasatinib in rat plasma, blood samples were obtained from the orbital vein. Using ultra-performance liquid chromatography-tandem mass spectrometry, the concentration of dasatinib was determined to obtain pharmacokinetic parameters.

Results

Compared to the dasatinib alone administration, the maximum concentration of the dasatinib plus Shenmai injection administration was decreased (355.9 ± 194.9 . 199.2 ± 73.8 ng·mL−1) ( < 0.05). Moreover, the area under the moment curve (3867.0 ± 2141.9 . 6355.3 ± 3311.6 ng·mL−1·h2) and mean residence time (3.7 ± 1.2 . 6.5 ± 3.1 h) showed a statistically significant increase ( < 0.05).

Conclusion

The study revealed that Shenmai injection might have the capacity to slow down the absorption rate of dasatinib and could extend the retention period of dasatinib in the body, resulting in stabilized blood drug concentrations and a reduction in adverse drug reactions.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdm/10.2174/0113892002336775250108112738
2025-01-30
2025-10-14

  • From This Site

    /content/journals/cdm/10.2174/0113892002336775250108112738
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SchwartzS.M. Epidemiology of cancer.Clin. Chem.202470114014910.1093/clinchem/hvad20238175589
     [Google Scholar]
  2. LinL. LiZ. YanL. LiuY. YangH. LiH. Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990–2019.J. Hematol. Oncol.202114119710.1186/s13045‑021‑01213‑z34809683
     [Google Scholar]
  3. LiuW. ZhangJ. YaoX. JiangC. HeJ. NiP. LiuJ. ChenQ. LiQ. ZangX. YaoL. LiuY. WangM. ShenP. WangG. ZhouF. Shenmai injection enhances the cytotoxicity of chemotherapeutic drugs against colorectal cancers via improving their subcellular distribution.Acta Pharmacol. Sin.201738226427610.1038/aps.2016.9927867186
     [Google Scholar]
  4. SunK. WuL. WangS. DengW. Antitumor effects of Chinese herbal medicine compounds and their nano-formulations on regulating the immune system microenvironment.Front. Oncol.20221294933210.3389/fonc.2022.94933236212483
     [Google Scholar]
  5. SuX.L. WangJ.W. CheH. WangC.F. JiangH. LeiX. ZhaoW. KuangH.X. WangQ.H. Clinical application and mechanism of traditional Chinese medicine in treatment of lung cancer.Chin. Med. J.2020133242987299710.1097/CM9.000000000000114133065603
     [Google Scholar]
  6. ZhangL. HuJ. XiaoL. ZhangY. ZhaoW. ZhengW. ShangH. Adverse drug reactions of Shenmai injection: A systematic review.J. Evid. Based Med.20103317718210.1111/j.1756‑5391.2010.01089.x21349063
     [Google Scholar]
  7. WangY. LiuQ. KongY. ZhongG. WangD. Efficacy and safety evaluation of Shenmai injections for dilated cardiomyopathy: A systematic review and meta-analysis of randomised controlled trials.Phytomedicine202311015463010.1016/j.phymed.2022.15463036608499
     [Google Scholar]
  8. WuY. LiT. LiP. PengH. GaoA. WangJ. ZhuH. WangX. Effects of Shenmai injection against chronic heart failure: A meta-analysis and systematic review of preclinical and clinical studies.Front. Pharmacol.202414133897510.3389/fphar.2023.133897538385058
     [Google Scholar]
  9. LuL. ZhengG. WangY. An overview of systematic reviews of shenmai injection for healthcare.Evid. Based Complement. Alternat. Med.20142014184065010.1155/2014/84065024669229
     [Google Scholar]
  10. ZhangS. MiY. YeT. LuX. LiuL. QianJ. FanX. Carbohydrates and ginsenosides in shenmai injection jointly improve hematopoietic function during chemotherapy-induced myelosuppression in mice.Chin. Med.202217112410.1186/s13020‑022‑00678‑536333798
     [Google Scholar]
  11. JiangS. SunB. ZhangY. HanJ. ZhouY. PanC. WangH. SiN. BianB. WangL. WangL. WeiX. ZhaoH. The immediate adverse drug reactions induced by ShenMai Injection are mediated by thymus-derived T cells and associated with RhoA/ROCK signaling pathway.Front. Immunol.202314113570110.3389/fimmu.2023.113570137026017
     [Google Scholar]
  12. FangT. LiJ. WuX. Shenmai injection improves the postoperative immune function of papillary thyroid carcinoma patients by inhibiting differentiation into Treg cells via miR-103/GPER1 axis.Drug Dev. Res.201879732433110.1002/ddr.2145930267584
     [Google Scholar]
  13. ZhongC. JiangC. NiS. WangQ. ChengL. WangH. ZhangQ. LiuW. ZhangJ. LiuJ. WangM. JinM. ShenP. YaoX. WangG. ZhouF. Identification of bioactive anti-angiogenic components targeting tumor endothelial cells in Shenmai injection using multidimensional pharmacokinetics.Acta Pharm. Sin. B20201091694170810.1016/j.apsb.2019.12.01133088689
     [Google Scholar]
  14. LiL. LiJ. WangQ. ZhaoX. YangD. NiuL. YangY. ZhengX. HuL. LiY. Shenmai injection protects against doxorubicin-induced cardiotoxicity via maintaining mitochondrial homeostasis.Front. Pharmacol.20201181510.3389/fphar.2020.0081532581790
     [Google Scholar]
  15. WuY.P. ZhangS. XinY.F. GuL.Q. XuX.Z. ZhangC.D. YouZ.Q. Evidences for the mechanism of Shenmai injection antagonizing doxorubicin-induced cardiotoxicity.Phytomedicine20218815359710.1016/j.phymed.2021.15359734111614
     [Google Scholar]
  16. ChengL. LiuW. ZhongC. NiP. NiS. WangQ. ZhangQ. ZhangJ. LiuJ. XuM. YaoX. CenX. WangG. JiangC. ZhouF. Remodeling the homeostasis of pro- and anti-angiogenic factors by Shenmai injection to normalize tumor vasculature for enhanced cancer chemotherapy.J. Ethnopharmacol.202127011377010.1016/j.jep.2020.11377033388426
     [Google Scholar]
  17. OlaleyeO.E. NiuW. DuF. WangF. XuF. PintusophonS. LuJ. YangJ. LiC. Multiple circulating saponins from intravenous ShenMai inhibit OATP1Bs in vitro: Potential joint precipitants of drug interactions.Acta Pharmacol. Sin.201940683384910.1038/s41401‑018‑0173‑930327544
     [Google Scholar]
  18. LiuS. ZhangK. HuX. Comparative efficacy and safety of Chinese medicine injections combined with capecitabine and oxaliplatin chemotherapies in treatment of colorectal cancer: A bayesian network meta-analysis.Front. Pharmacol.202213100425910.3389/fphar.2022.100425936523501
     [Google Scholar]
  19. GuD. HuangL. ChenX. WuQ. DingK. Structural characterization of a galactan from Ophiopogon japonicus and anti-pancreatic cancer activity of its acetylated derivative.Int. J. Biol. Macromol.201811390791510.1016/j.ijbiomac.2018.03.01929518447
     [Google Scholar]
  20. OuyangY. TangL. HuS. TianG. DongC. LaiH. WangH. ZhaoJ. WuH. ZhangF. YangH. Shengmai san-derived compound prescriptions: A review on chemical constituents, pharmacokinetic studies, quality control, and pharmacological properties.Phytomedicine202210715443310.1016/j.phymed.2022.15443336191550
     [Google Scholar]
  21. YuK. MaY. ShaoQ. QuH. ChengY. Simultaneously determination of five ginsenosides in rabbit plasma using solid-phase extraction and HPLC/MS technique after intravenous administration of ‘SHENMAI’ injection.J. Pharm. Biomed. Anal.200744253253910.1016/j.jpba.2007.01.03217317071
     [Google Scholar]
  22. YangJ. LiY. ChauC.I. ShiJ. ChenX. HuH. UngC.O.L. Efficacy and safety of traditional Chinese medicine for cancer-related fatigue: A systematic literature review of randomized controlled trials.Chin. Med.202318114210.1186/s13020‑023‑00849‑y37907925
     [Google Scholar]
  23. ZhangX. LvS. ZhangW. JiaQ. WangL. DingY. YuanP. ZhuY. LiuL. LiY. ZhangJ. Shenmai injection improves doxorubicin cardiotoxicity via miR-30a/Beclin 1.Biomed. Pharmacother.202113911158210.1016/j.biopha.2021.11158233895525
     [Google Scholar]
  24. ZhouY. ZhaoB. WuW. YangX. LongS. DengH. HeW. LiaoG. LiQ. XieZ. Shenmai injection for the treatment of cancer-related fatigue in advanced non-small cell lung cancer patients undergoing chemotherapy: Study protocol for a randomized controlled trial.Trials201819147410.1186/s13063‑018‑2845‑730180874
     [Google Scholar]
  25. QinG. XuT. LvX. JiangS. ZhangK. XuM. FuL. WuQ. ZhouY. Efficacy and safety of a combination of shenmai injection plus chemotherapy for the treatment of lung cancer: A meta-analysis.Evid. Based Complement. Alternat. Med.2021202111310.1155/2021/792916533936245
     [Google Scholar]
  26. CerchioneC. LocatelliF. MartinelliG. Dasatinib in the management of pediatric patients with philadelphia chromosome-positive acute lymphoblastic leukemia.Front. Oncol.20211163223110.3389/fonc.2021.63223133842339
     [Google Scholar]
  27. Duque-AfonsoJ. LinC.H. HanK. MorgensD.W. JengE.E. WengZ. JeongJ. WongS.H.K. ZhuL. WeiM.C. ChaeH.D. SchrappeM. CarioG. DuysterJ. XiaoX. SakamotoK.M. BassikM.C. ClearyM.L. CBP modulates sensitivity to dasatinib in Pre-BCR+ acute lymphoblastic leukemia.Cancer Res.201878226497650810.1158/0008‑5472.CAN‑18‑170330262461
     [Google Scholar]
  28. JabbourE. Chronic myeloid leukemia: First-line drug of choice.Am. J. Hematol.2016911596626769227
     [Google Scholar]
  29. KeatingG.M. Dasatinib: A review in chronic myeloid leukaemia and Ph+ acute lymphoblastic leukaemia.Drugs2017771859628032244
     [Google Scholar]
  30. LevêqueD. BeckerG. BilgerK. Natarajan-AméS. Clinical pharmacokinetics and pharmacodynamics of dasatinib.Clin. Pharmacokinet.202059784985610.1007/s40262‑020‑00872‑432112275
     [Google Scholar]
  31. JabbourE. CortesJ. KantarjianH. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.Expert Opin. Investig. Drugs200716567968717461740
     [Google Scholar]
  32. Fauziya GuptaA. NadafA. AhmadS. HasanN. ImranM. SahebkarA. JainG.K. KesharwaniP. AhmadF.J. Dasatinib: A potential tyrosine kinase inhibitor to fight against multiple cancer malignancies.Med. Oncol.202340617337165283
     [Google Scholar]
  33. AraujoJ. LogothetisC. Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors.Cancer Treat. Rev.201036649250010.1016/j.ctrv.2010.02.01520226597
     [Google Scholar]
  34. McCormackP.L. KeamS.J. Dasatinib.Drugs201171131771179510.2165/11207580‑000000000‑0000021902298
     [Google Scholar]
  35. WongS.F. New dosing schedules of dasatinib for CML and adverse event management.J. Hematol. Oncol.2009211010.1186/1756‑8722‑2‑1019236716
     [Google Scholar]
  36. ChengY.Y. HsiehC.H. TsaiT.H. Concurrent administration of anticancer chemotherapy drug and herbal medicine on the perspective of pharmacokinetics.Yao Wu Shi Pin Fen Xi2018262SS88S9529703390
     [Google Scholar]
  37. MaW. LvL. GuoJ. MengY. WangY. YangX. ZhuL. NianH. ZhaoL. Effects of xuesaitong on the pharmacokinetics of losartan: An in vivo UPLC-MS/MS study.Evid. Based Complement. Alternat. Med.201920191810.1155/2019/837347631511782
     [Google Scholar]
/content/journals/cdm/10.2174/0113892002336775250108112738
Loading
Effects of Shenmai Injection on the Pharmacokinetics of Dasatinib: An In-Depth In vivo Analysis Utilizing UPLC-MS/MS Technique
Current Drug Metabolism 25, 670 (2024); https://doi.org/10.2174/0113892002336775250108112738
/content/journals/cdm/10.2174/0113892002336775250108112738
/content/journals/cdm/10.2174/0113892002336775250108112738
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): dasatinib; drug interactions; pharmacokinetics; Shenmai injection; traditional chinese medicine; UPLC-MS/MS

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test